Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000808773 | SCV000948893 | uncertain significance | Arterial tortuosity syndrome | 2022-07-19 | criteria provided, single submitter | clinical testing | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SLC2A10 protein function. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. ClinVar contains an entry for this variant (Variation ID: 653077). This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 337 of the SLC2A10 protein (p.Gly337Arg). This variant is present in population databases (rs369238826, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with SLC2A10-related conditions. |
| Gene |
RCV004768672 | SCV005379990 | uncertain significance | not provided | 2023-12-18 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function |